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Abstract
Background: A sensitive and analytically specific nucleic acid amplification test (NAAT) is valuable in confirming
the diagnosis of early Lyme disease at the stage of spirochetemia.
Findings: Venous blood drawn from patients with clinical presentations of Lyme disease was tested for the
standard 2-tier screen and Western Blot serology assay for Lyme disease, and also by a nested polymerase chain
reaction (PCR) for B. burgdorferi sensu lato 16S ribosomal DNA. The PCR amplicon was sequenced for B. burgdorferi
genomic DNA validation. A total of 130 patients visiting emergency room (ER) or Walk-in clinic (WALKIN), and 333
patients referred through the private physicians’ offices were studied. While 5.4% of the ER/WALKIN patients
showed DNA evidence of spirochetemia, none (0%) of the patients referred from private physicians’ offices were
DNA-positive. In contrast, while 8.4% of the patients referred from private physicians’ offices were positive for the
2-tier Lyme serology assay, only 1.5% of the ER/WALKIN patients were positive for this antibody test. The 2-tier
serology assay missed 85.7% of the cases of early Lyme disease with spirochetemia. The latter diagnosis was
confirmed by DNA sequencing.
Conclusion: Nested PCR followed by automated DNA sequencing is a valuable supplement to the standard 2-tier
antibody assay in the diagnosis of early Lyme disease with spirochetemia. The best time to test for Lyme
spirochetemia is when the patients living in the Lyme disease endemic areas develop unexplained symptoms or
clinical manifestations that are consistent with Lyme disease early in the course of their illness.
Background
Lyme disease is a tick-borne human infection which is
an imperative differential diagnosis for internal medicine
physicians offering primary care to ambulatory patients
in the endemic counties of the United States. Hemato-
genous dissemination of the Borrelia burgdorferi spiro-
chetes from the initial skin site of a tick bite is believed
to cause secondary skin lesions and extracutaneous
manifestations in Lyme disease [1]. Borrelia spirochete-
mia, when validated, provides reliable objective evidence
for the diagnosis of early Lyme disease, based on which
timely appropriate treatment is instituted to avoid tissue
damage and to prevent the infection from going into
chronic phase. However, B. burgdorferi spirochetemia is
transient, and the culture techniques which require at
least 9 mL of plasma sample and may take several
weeks to recover [2] are not practical as a routine diag-
nostic tool. Pathogenic Borrelia burgdorferi cells are
known to exist in non-dividing or slowly dividing forms
which may not generate a visible positive growth in arti-
ficial media at all [3]. The diagnosis of early Lyme dis-
ease has been a challenging task for the primary contact
physicians practicing in the endemic areas [4].
The polymerase chain reaction (PCR) technologies for
the study of the most conserved genospecies-specific
Borrelia burgdorferi sensu lato16S ribosomal RNA gene,
or 16S rDNA, have been used in epidemiology research
[5,6]. Using a pair of specific TEC1 and LD2 primers for
PCR, the chances of non-specific amplification of 16S
rDNA derived from spirochetes unrelated to Lyme dis-
ease are minimized [7]. However, little attempt has been
made to transfer this procedure into clinical laboratory
practice because the method is not robust enough for
routine diagnostic applications. We have recently refined
this research tool with a nested PCR technology for DNA
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for validation of the genospecies-specific B. burgdorferi
sensu lato 16S rDNA in patient body fluids to further
augment the sensitivity and specificity of the procedure
as a clinical laboratory test [8]. Since the base sequence
of the PCR-amplified spirochete DNA in this procedure
is routinely validated by online sequence alignment algo-
rithms with the GenBank database with a 100% identities
match with an exclusive unique sequence for the molecu-
lar diagnosis to be established, there are no false positive
results due to molecular misidentification. The nested
PCR technology has increased the sensitivity of the com-
m o n l yu s e do n e - r o u n dP C RN A A Tf o rL y m es p i r o c h e t e
DNA by 100-1000 fold [8]. This report summarizes our
experience in using this routine clinical laboratory test
for molecular diagnosis of B. burgdorferi spirochetemia in
an endemic suburban town during a summer season.
Methods
From May 1 to November 30, 2009, 463 paired samples of
EDTA-anticoagulated venous blood and venous blood
without additives from patients suspected of having Lyme
disease were received by the Milford Hospital-affiliated
Milford Medical Laboratory to be tested for Lyme disease.
Of these 463 pairs of blood samples, 130 were collected
on the order of the physicians working in the hospital
emergency room (ER) and walk-in clinic (WALKIN)
because clinical manifestations of the patients were sug-
g e s t i v eo fL y m ed i s e a s ew i t ho rw i t h o u tt h eh i s t o r yo fa
recent tick bite. Milford is a suburban town in Connecti-
cut in which Lyme disease is endemic.
Milford Hospital is a community hospital. Its ER and
WALKIN have about 40,000 patient visits a year. The
local residents and practicing physicians are aware that
Lyme borreliosis should always be a differential diagno-
sis during the months from spring to fall when a patient
presents with a recent onset of fatigue, skin rash, fever,
muscle aches, neck pain, joint pains or lymphadenopa-
thy, without a clear etiology. These symptoms and signs
which may vary from patient to patient are recognized
as common clinical presentations in early Lyme disease
in the United States [9].
The remaining 333 pairs of blood samples were from
patients referred by their primary care private physicians
in the area for possible Lyme disease.
The 130 ER/WALKIN patients had an age range
between 14 and 84 years old with a median age of 42.
In comparison, the 333 patients referred from the pri-
vate physicians’ offices had an age range between 11 and
89 with a median age of 51.
For every pair of the blood samples received, the
plasma was separated from the EDTA-blood for nested
PCR/DNA sequencing for the detection of B. burgdorferi
16S rDNA, which was performed at the Milford Medical
Laboratory, a clinical laboratory approved by the
Department of Public Health, State of Connecticut,
under the Clinical Laboratory Improvement Act of 1988
to perform high-complexity laboratory testing, including
PCR and DNA sequencing for the molecular identifica-
tion of Borrelia burgdorferi. The latter methodology was
published elsewhere [8]. Briefly, a 100 μL aliquot of the
patient plasma was mixed with 200 μL 0.7 M ammo-
nium hydroxide in a 1.5 mL Eppendorf tube for DNA
extraction. The mixture was heated at 95-98°C for 5
min with closed cap, followed by 10 min with open cap.
After the tube was cooled to room temperature, 700 μL
of 95% ethanol and 30 μL of 3 M sodium acetate were
added to the mixture. The mixture was centrifuged at
13,000 rpm (~16,000 g)f o r5m i na n dt h es u p e r n a t a n t
discarded. The precipitate was re-suspended in 1 mL of
cold 70% ethanol. Then the suspension was centrifuged
at 13,000 rpm for 5 min. After all liquid was discarded,
the pellet was air-dried and re-suspended in 100 μLT E
buffer with heating at 95-98°C for 5 min. The heated
suspension was finally centrifuged at 13,000 rpm for 5
min. One μL of the supernatant was used for primary
PCR to be followed by nested PCR amplification without
further purification, using a ready-to-use HiFi® DNA
polymerase LoTemp® PCR mix (HiFi DNA Tech, LLC,
Trumbull, CT) in a total volume of 25 μL. A trace of
the primary PCR products without purification was
transferred by a micro glass rod to another 25 μL
LoTemp® PCR mix containing a pair of heminested
(nested) primers for nested PCR amplification.
The primary PCR primers used were nucleotides LD1
(5’-ATGCACACTTGGTGTTAACTA) and LD2 (5’-GAC
TTATCACCGGCAGTCTTA) [5]. The nested PCR pri-
mers were nucleotides TEC1 (5’-CTGGGGAGTATGC
TCGCA AGA) [7] and LD2 [5]. The thermocycling steps
were programmed to 30-cycles at 85°C for 30 seconds, 50°
C for 30 seconds, and 65°C for 1 minute after an initial
heating for 10 minutes at 85°C, with a final extension at
65°C for 10 minutes for both primary and nested PCR in a
TC-412 Thermal Cycler (Techne Incorporated, Burling-
ton, NJ). All positive nested PCR products showing a band
of expected target size on gel electrophoresis were sub-
jected to direct automated DNA sequencing, using TEC1
nucleotide as the sequencing primer.
The serum sample was submitted for Lyme disease
antibody screen by the 2-tier immunoglobulin M (IgM)
and immunoglobulin G (IgG) enzyme-linked immuno-
sorbent assay (ELISA) and Western Blot for the detection
of antibodies against sonicated whole-cell B. burgdorferi
by Quest Diagnostics Incorporated, Wallingford, CT, a
recognized commercial reference clinical laboratory,
according to the CDC guidelines [10].
Publication of general analytical data extracted from
hospital records with concealed patient identities was
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Board.
Results
As previously reported, nested PCR amplification of the
conserved segment of B. burgdorferi sensu lato 16S
rDNA for signature sequence analysis generated a 293
base-pair (bp) amplicon with the TEC1 and LD2 pri-
mers. After confirming a 100% identities match with a
unique specific DNA sequence for B. burgdorferi sensu
lato 16S rDNA stored in the GenBank database using
the online Basic Local Alignment Search Tool (BLAST),
the molecular identification of the nested PCR product
as a genomic DNA of B. burgdorferi was established
beyond a reasonable doubt. BLAST analysis of a 50-60
bp sequence downstream of the LD2 primer-binding
s i t ew a sm o r et h a na d e q u a t et oa c h i e v eav e r yl o wE -
value, which indicates that the chance of molecular mis-
identification is infinitesimal. A segment of the electro-
pherogram containing the signature nucleotide sequence
(Figure 1) was incorporated in the laboratory report for
completion of an evidence-based molecular diagnosis of
Lyme borrelia spirochetemia.
Our experience confirmed that PCR is not a specific
tool for DNA identification, especially for the diagnosis
of Lyme disease. From this series of 436 patients, 3
plasma samples were found to contain non-target DNA
which led to generation of PCR products of a molecular
size similar, but not identical, to that of the B. burgdor-
feri 16S rDNA. These non-Lyme disease DNA molecules
were amplified by the PCR primer pair designed for B.
burgdorferi DNA replication. However, in the absence of
a fully matched B. burgdorferi target DNA template,
these unintended and non-target DNA molecules were
amplified by the partially matched primers during the
highly sensitive nested PCR process. One of such non-
target PCR amplicons was only 6-bp shorter than the
expected 293-bp B. burgdorferi 16S rDNA fragment, as
observed on gel electrophoresis (Figure 2). Only DNA
sequencing could confirm that it was really a 287-bp
16S rDNA fragment of an environmental bacterium
(Figure 3). As indicated in the GenBank database, the
primer binding sites selected for PCR amplification of
the most conserved 16S ribosomal RNA gene of the
genospecies of Borrelia burgdorferi sensu lato also bear
great similarities in DNA sequence with the 16S riboso-
mal RNA genes of other bacterial species (Figure 4).
There was an obvious difference in the test results
between the 333 blood samplep a i r sf r o mt h ep a t i e n t s
referred to the laboratory by the individual private
Figure 1 DNA sequencing of Borrelia burgdorferi 16S rDNA detected in the plasma of a spirochetemic patient. This 58-base sequence
was excised from an electropherogram generated by an ABI 3130 genetic analyzer. The template was the nested PCR amplicon generated by
the TEC1 and LD2 primers. The sequencing primer was TEC1. BLAST alignment analysis validates the molecular diagnosis of hematogenous
dissemination of Lyme disease in this patient. ABI, Applied Biosystems, Foster City, CA.
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patients seen by the physicians at the ER and WALKIN.
Of the blood samples from the former group of 333
patients, 28 (28/333), namely 8.4%, were found to be
positive for the 2-tier IgM and IgG ELISA screen and
further confirmed by Western Blot for the detection of
antibodies against sonicated whole-cell B. burgdorferi.
But all of the 333 companion plasma samples in this
group were negative for B. burgdorferi nested PCR
NAAT, indicating that there was no evidence of spiro-
chetemia in these patients (Table 1).
Of the blood sample pairs collected from the 130
patients visiting the ER and WALKIN, 2 (2/130), namely
1.5%, were found to be positive for the 2-tier Lyme dis-
ease serology test, and 7 (7/130), namely 5.4%, were
found to contain B. burgdorferi 16S rDNA. Of the 2
patients in this group, whose serum was positive for the
2-tier antibody test for Lyme disease, 1 was also found
to have circulating B. burgdorferi DNA in the compa-
nion plasma. The other sero-positive patient did not
have evidence of B. burgdorferi spirochetemia when the
2-tier Lyme disease antibody test became positive. In
other words, among the 7 ER/WALKIN patients pre-
senting with spirochetemia, 6 had B. burgdorferi DNA
in their blood without the characteristic antibodies
while 1 patient had both B. burgdorferi DNA and the
characteristic Lyme disease antibodies in the blood
(Table 2).
At the spirochetemic stage, 3 of the 7 patients had
skin rashes. Two of the 3 skin lesions presented with a
“bull’s eye” appearance, considered typical of Lyme dis-
ease, and 1 was described as “hives”. Most of the spiro-
chetemic patients (5/7) stated that the duration of their
chief complaint symptoms and signs lasted for about 24
hours before they decided to seek immediate medical
attention. Two (2/7) of the patients had multiple joint
pains or headaches for about 3 weeks before visiting the
ER/WALKIN after noticing an additional chest pain or a
Figure 2 Gel electrophoresis of nested PCR products of DNA
from the plasma of a patient suspicious of Lyme disease (M09-
2475). The sample was amplified by the TEC1 and LD2 primers and
one major band had the molecular weight indistinguishable from
the B. burgdorferi DNA control. P = B. burgdorferi 16S rDNA nested
PCR amplicon control; molecular size 293 base pairs. M09-2475 =
Nested PCR products of questionable DNA isolated from a patient’s
plasma. The nested PCR was performed in triplicate to ensure
technical accuracy. M = Molecular ruler. N = Negative control to
rule out reagent contamination.
Figure 3 DNA sequencing of the nested PCR products of case M09-2475, as illustrated in Figure 2. The 21-base LD2 PCR primer-binding
site for B. burgdorferi is marked on the right. A 60-base sequence on the left is validated to be that of a Pusillimonas 16S rDNA based on
GenBank database. This is a typical example of environmental bacterial 16S rDNA in patient’s blood masquerading as B. burgdorferi 16S rDNA.
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ochetemic patients registered a fever. On 4 patients for
whom a CBC was ordered, 3 (3/4) showed slight leukocy-
tosis with an increased percentage of neutrophils. One
patient who had a concomitant chronic liver disease
showed evidence of leukopenia. None of the 7 spiroche-
temic patients recalled a history of recent tick bites.
As stated above, only one of the 7 spirochetemic
patients (1/7) was found to be positive for the 2-tier
serology test at the time of the initial visit. Follow-up
information obtained from the primary care physicians
of the patients confirmed that all presenting clinical
symptoms and signs ascribed to Lyme borreliosis
resolved completely after treatment with oral doxycy-
cline, without recurrences in the ensuing 6-11 months.
Only one of the 6 spirochetemic patients who were
serologically negative at the initial visit was re-tested
for possible rising antibody titers of Lyme disease, and
the serology re-testing result was also negative. The
major relevant clinical findings of the 7 spriochetemic
patients were summarized in Table 3.
Discussion
Accurate diagnosis of early Lyme disease plays a pivotal
role in “curing” the infection with appropriate antibiotic
treatment, and in preventing the infection from going
into chronic phase which may cause debilitating tissue
damage. However, the clinical manifestations of early
Lyme disease are highly variable and often not easily
distinguished from those caused by other illnesses. The
commonly used 2-tier serology laboratory test which
usually only turns positive during convalescence of the
infection is reported to be negative or non-diagnostic in
75% of the “clinically confirmed” cases of early Lyme
disease [4]. Testing for B. burgdorferi spirochetemia has
been suggested to be the laboratory approach to diag-
nose early Lyme disease at the stage of hematogenous
dissemination of the bacteria, which is believed to
Figure 4 Two partial DNA sequences retrieved from the National Center for Biotechnology Information database. (a) GenBank Locus
GQ247740, a 293-base long signature sequence for B. burgdorferi 16S rDNA. TEC1 (left) and LD2 (right) PCR primer sites underlined. (b) GenBank
Locus FJ948170, a 287-base long sequence of 16S rDNA for numerous environmental bacteria. TEC1 and LD2 primer sites underlined. Note 6
mismatched bases printed in red bold face. X———— = 231 bases in a sequence specific and unique for B. burgdorferi 16S rDNA. X = 225
bases in a sequence nonspecific for environmental bacterial 16S rDNA. 000000 = 6 slots with no nucleotide bases. In the absence of a fully
matched B. burgdorferi DNA, the PCR primers may bind to a partially matched non-target bacterial DNA templates which are not infrequently
present in normal human blood. Only DNA sequencing can distinguish the 287 base-pair PCR amplicon of a common environmental bacterial
16S rDNA from a 293-base B. burgdorferi 16S rDNA.
Table 1 Comparison of nested PCR and 2-tier serology in
detection of Lyme disease among 333 patients referred
by private practitioners from offices
Two-tier Serology Total
+-
Nested PCR + 0 0 0
Nested PCR - 28 305 333
Total 28 305 333
+ = positive.
- = negative.
Laboratory detection of Lyme disease among 333 patients referred from
private offices:
Confirmed case prevalence = 28/333 = 8.4% (2-tier serology only).
Sensitivity of nested PCR = 0% (0/28).
Sensitivity of 2-tier seropositivity = 100% (28/28).
Table 2 Comparison of nested PCR and 2-tier serology in
detection of Lyme disease among 130 patients visiting
emergency room and walk-in clinic
Two-tier Serology Total
+-
Nested PCR + 1 6 7
Nested PCR - 1 122 123
Total 2 128 130
+ = positive.
- = negative.
Laboratory detection of Lyme disease among 130 ER/walkin patients:
Confirmed case prevalence = (7+1)/130 = 8/130 = 6.2% (DNA sequencing or
2-tier serology).
Sensitivity of nested PCR = 87.5% (7/8).
Sensitivity of 2-tier seropositivity = 25% (2/8).
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Page 5 of 8Table 3 Clinical summary of 7 early Lyme disease patients with spirochetemia
Age/Sex Chief Complaint Duration Temp °F CBC Results? Hx Tick Bite? Skin Lesion? Serology Follow up Serology
1) 43/M Hives; Thoracic Spine Pain 24 hr 98.0 Not Done NO YES ELISA = +, WB IgM = + NONE
2) 39/F Bilateral Leg Pain, Headache 24 hr 98.1 7.2 WBC; Elev Neut% NO NO ELISA = - WB = - NONE
3) 15/F Shoulder Pain; Bilateral Leg Pain 24 hr 96.8 4.8 WBC; Elev Neut% NO NO ELISA = - ELISA = - 2 wks later
4) 43/M Bull’s eye rash 24 hr 98.3 Not Done NO YES ELISA = -, WB = - NONE
5) 22/M Painful Inguinal Lymphadenopathy 24 hr 98.6 Not Done NO NO ELISA = -, WB = - NONE
6) 52/M Multiple Joint Pain/Chest Pain 3 weeks/72 hr 97.7 10.8 WBC; Elev Neut% NO NO ELISA = - NONE
7) 55/F Headache, Bull’s eye rash ? 3 weeks 98.5 3.5 WBC; Decreased Neut% NO YES ELISA = - NONE
L
e
e
e
t
a
l
.
B
M
C
R
e
s
e
a
r
c
h
N
o
t
e
s
2
0
1
0
,
3
:
2
7
3
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
7
5
6
-
0
5
0
0
/
3
/
2
7
3
P
a
g
e
6
o
f
8precede the appearance of the diagnostic antibodies
[1,2,4]. However, the traditional microbiology blood cul-
ture techniques are not practical for the diagnosis of
Lyme disease because it takes several weeks to recover a
positive growth of the Lyme spirochetes in the liquid
media. Attempts to culture B. burgdorferi spirochetes
from patients’ blood as a diagnostic tool have largely
resulted in disappointments [11]. Non-dividing or slowly
dividing Borrelia burgdorferi cells which do not generate
a discernible positive culture in artificial liquid media
are known to cause infections in animals [3]. The other
alternative to detect this fastidious infectious agent in a
patient’s blood is to test for its genetic fingerprint mate-
rials, namely by a NAAT.
Several PCR-based nucleic acid amplification tests
have been used for the detection of B. burgdorferi DNA
in the blood samples of patients suffering from Lyme
disease. However, their sensitivity is generally too low to
be useful for clinical application [12-15] in part due to a
lack of consistency of the Borrelia burgdorferi genetic
materials targeted for PCR amplification by these meth-
ods. The lack of rigorous validation of the PCR products
has also caused false positive results which can lead to
inappropriate treatment with potentially serious compli-
cations [16,17]. Adoption of a NAAT procedure for the
diagnosis of Lyme disease must proceed with caution.
Since all bacteria contain a 16S ribosomal RNA gene,
or 16S rDNA, which differs from one another in their
respective unique hypervariable regions, three oligonu-
cleotide PCR primers, known as LD1, LD2 [5,6], and
TEC1 [7], have been introduced to amplify a highly con-
served region of the B. burgdorferi sensu lato 16S rDNA
for its molecular fingerprint identification. In combina-
tion with the nested PCR and direct automated DNA
sequencing technologies, these genospecies-specific PCR
primers are useful in generating reliable materials for
sequence alignment analysis using the online GenBank
database as the standard for validation of the B. burg-
dorferi sensu lato 16S rDNA [8]. The potential value of
their clinical application in confirmation of early Lyme
disease spirochetemia has been demonstrated by the
results presented in this report.
One potential pitfall in targeting a highly conserved
bacterial16S rDNA of the genospecies of B. burgdorferi
sensu lato for molecular diagnosis of Lyme borrelia spir-
ochetemia is that some environmental bacterial 16S
rDNA fragments, which may be present in normal
human blood samples [18,19], can be amplified by the
chosen PCR primers, especially when the nested PCR
technology is employed to increase the detection sensi-
tivity (Figures 2, 3, 4). This kind of potential false posi-
t i v er e s u l tg e n e r a t e db yan o n - s p e c i f i cP C Rc a nb e
eliminated by routine direct DNA sequencing of all
putative PCR-positive materials with their signature
sequences validated through online GenBank sequence
alignment algorithms (Figure 1).
In one residential suburb where Lyme disease is ende-
mic, we found that 5.4% of the ER/WALKIN patients
presenting with Lyme disease-like clinical manifestations
were shown to have B. burgdorferi spirochetemia while
none (0%) of the patients referred to the laboratory
from their private doctors’ offices with the same differ-
ential diagnosis had evidence of spirochetemia when
tested by the same procedure. In comparison, only 1.5%
o ft h eE R / W A L K I Np a t i e n t si nt h es a m eg r o u pw e r e
positive for the 2-tier antibody serology test for Lyme
disease while 8.4% of the patients referred from the pri-
vate doctors’ offices were positive for the 2-tier serology
test. These findings seem to indicate that the best time
for detecting spirochetemia in early Lyme disease is
when the onset of the clinical manifestations is noticed
by the patient. Such immediate medical attention is
probably only available at the ER or WALKIN in most
endemic regions. Waiting for a scheduled appointment
to the regular private doctor’s office may miss the win-
dow of opportunity in DNA detection at the time when
the Lyme disease bacteria are circulating in the blood,
but only briefly.
In our series, 6 of the 7 (85.7%) PCR-detected, DNA
sequencing-confirmed Lyme spirochetemic patients did
not develop the 2-tier Lyme disease antibodies at the
time of initial laboratory testing. Since these patients
were all suspected of suffering from Lyme borreliosis
based on clinical manifestations alone, they were pre-
scribed a short course of preventive doxycycline while
waiting for the laboratory test results. The antibiotics
would be discontinued when the 2-tier serology screen
test and the PCR test results were both found to be
negative. All ER/WALKIN patients were referred back
to their regular primary care physicians for follow up,
and most private healthcare practitioners did not order
additional serology tests for these patients. Therefore, it
is not known if these 6 sero-negative, proven spirochete-
mic patients would turn sero-positive for the 2-tier ser-
ology test during their long-term convalescence. If no
further follow-up serology tests were ordered, or if the
subsequent 2-tier antibody tests turned out to be nega-
tive as a result of the initial partial treatment [20,21],
these 6 Lyme disease patients would have been classified
as having “no evidence of Lyme disease”, except for the
DNA evidence of Lyme spirochetemia. These clinical
observations emphasize the importance of public educa-
tion in the diagnosis of Lyme borrrelial spirochetemia.
Early Lyme disease is essentially a patient-initiated
laboratory diagnosis under the guidance of an alert phy-
sician. The patients generally control the window of
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transient and brief. The time points of spirochetemia
may vary from patient to patient.
Conclusion
We found DNA evidence of B. burgdorferi spirochete-
mia in 7 of 130 (5.4%) ER/WALKIN patients with clini-
cal manifestations of early Lyme disease. During the
same period, we found no DNA evidence of spirochete-
mia in 333 patients who were referred from private phy-
sicians’ offices for Lyme disease tests. In comparison, 28
of the 333 (8.7%) patients from the private physicians’
offices were positive for the 2-tier Lyme disease anti-
body test whereas only 2 of the 130 (1.5%) ER/WALKIN
patients were positive for the 2-tier serology test. Only 1
of the ER/WALKIN patients was positive both for the
B. burgdorferi DNA and for the 2-tier antibody test at
the same time. Based on these findings, we conclude
that molecular testing for detection of B. burgdorferi
spirochetemia should be a supplement to the standard
2-tier serology assay for all ER/WALKIN patients with
clinical manifestations of early Lyme disease. Relying on
a serology test alone may miss the diagnosis of 85.7% of
the early Lyme disease, which can be confirmed by a
blood NAAT for spirochetemia.
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